AGN
vs
S
S&P/ASX 300
AGN
Over the past 12 months, AGN has underperformed S&P/ASX 300, delivering a return of -67% compared to the S&P/ASX 300's +5% growth.
Stocks Performance
AGN vs S&P/ASX 300
Performance Gap
AGN vs S&P/ASX 300
Performance By Year
AGN vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Argenica Therapeutics Ltd
Glance View
Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.
